UroGen Pharma Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019	2018	2017	2016	2015
Revenue	82.71	64.36	48.04	11.8	0.02	1.13	8.16	17.53	0
Revenue Growth (YoY)	28.52%	33.96%	307.17%	65450.00%	-98.40%	-86.17%	-53.46%	-	-
Cost of Revenue	9.36	7.65	5.16	1.01	0	1.8	0.6	0.03	0
Gross Profit	73.35	56.7	42.89	10.79	0.02	-0.68	7.56	17.5	0
Selling, General & Admin	93.27	82.84	87.54	90.22	60.2	39.57	8.81	6.42	1.9
Research & Development	45.61	52.91	47.64	47.31	49.3	36.93	18.7	10.29	10.52
Operating Expenses	138.89	135.74	135.18	137.53	109.5	76.51	27.51	16.7	12.41
Operating Income	-65.54	-79.04	-92.29	-126.74	-109.48	-77.18	-19.95	0.8	-12.41
Interest Expense / Income	14.72	8.44	0	0	0	-1.65	0.03	2.74	0.28
Other Expense / Income	18.07	20.55	17.08	-1.63	-4.33	-	-	-	-
Pretax Income	-98.32	-108.03	-109.37	-125.11	-105.15	-75.53	-19.98	-1.94	-12.69
Income Tax	3.92	1.76	1.45	3.37	0	0.13	0.02	0	0
Net Income	-102.24	-109.78	-110.82	-128.48	-105.15	-75.66	-20	-1.94	-12.69
Shares Outstanding (Basic)	29	23	22	22	21	16	10	2	2
Shares Outstanding (Diluted)	29	23	22	22	21	16	10	2	2
Shares Change	26.43%	2.06%	2.60%	6.10%	30.31%	62.13%	321.46%	0.20%	-
EPS (Basic)	-3.55	-4.81	-4.96	-5.90	-5.12	-4.80	-2.14	-1.91	-5.88
EPS (Diluted)	-3.55	-4.81	-4.96	-5.90	-5.12	-4.80	-2.14	-1.91	-5.88
Free Cash Flow	-76.57	-87.81	-85.64	-107.1	-71.34	-37.89	-9.84	3.49	-7.48
Free Cash Flow Per Share	-2.66	-3.85	-3.83	-4.92	-3.48	-2.40	-1.01	1.52	-3.25
Gross Margin	88.68%	88.11%	89.27%	91.45%	100.00%	-59.84%	92.65%	99.84%	-
Operating Margin	-79.23%	-122.82%	-192.11%	-1074.15%	-608211.11%	-6842.20%	-244.55%	4.55%	-
Profit Margin	-123.61%	-170.58%	-230.67%	-1088.94%	-584144.44%	-6707.18%	-245.16%	-11.07%	-
Free Cash Flow Margin	-92.57%	-136.45%	-178.27%	-907.71%	-396344.44%	-3359.40%	-120.61%	19.93%	-
EBITDA	-81.9	-97.77	-107.6	-123.07	-103.82	-76.76	-19.74	1.01	-12.3
EBITDA Margin	-99.02%	-151.92%	-223.97%	-1043.02%	-576788.89%	-6805.23%	-242.01%	5.77%	-
Depreciation & Amortization	1.71	1.82	1.77	2.04	1.32	0.42	0.21	0.21	0.11
EBIT	-83.61	-99.59	-109.37	-125.11	-105.15	-77.18	-19.95	0.8	-12.41
EBIT Margin	-101.08%	-154.75%	-227.66%	-1060.34%	-584144.44%	-6842.20%	-244.55%	4.55%	-

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).